Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Statin plus bifidobacterium capsules for enhanced Lp(a) reduction
ChiCTR2300075769Phase 4Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Apr 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of atorvastatin, rosuvastatin and Golden Bifid in hyperlipidemia, coronary arteriosclerosis, arteriosclerosis obliterans and 1 more (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Lp(a) (mg/l). Started Apr 2023; status: completed.
02
Drugs
atorvastatinrosuvastatinGolden Bifid
03
Conditions
hyperlipidemiacoronary arteriosclerosisarteriosclerosis obliteransCardiac valve disease (VHD)
Beyond the preview
Go deeper on ChiCTR2300075769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075769.